BPC-157 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
(G71.3) Mitochondrial myopathies, which are due to defects in mitochondria, which provide a critical source of energy for muscle (G72.3) Familial periodic paralysis (G72.4) Inflammatory myopathies, which are caused by problems with the immune system attacking components of the muscle, leading to signs of inflammation in the muscle (G73.6) Metabolic myopathies, which result from defects in biochemical metabolism that primarily affect muscle (G73.6/E74.0) Glycogen storage diseases, which may affect muscle (G73.6/E75) Lipid storage disorder (G72.89) Other myopathies Brody myopathy Congenital myopathy with abnormal subcellular organelles Fingerprint body myopathy Inclusion body myopathy 2 Megaconial myopathy Myofibrillar myopathy Rimmed vacuolar myopathy
British rule ended on 30 November 1967, when the People's Republic of Southern Yemen gained independence, and in line with other formerly British Arab territories in the Middle East, it did not join the Commonwealth of Nations.
==== 1.B. β-Barrel porins and other outer membrane proteins ==== 1.B.1 General bacterial porin family 1.B.2 Chlamydial porin (CP) family 1.B.3 Sugar porin (SP) family 1.B.4 Brucella-Rhizobium porin (BRP) family 1.B.5 Pseudomonas OprP porin (POP) family 1.B.6 OmpA-OmpF porin (OOP) family 1.B.7 Rhodobacter PorCa porin (RPP) family 1.B.8 Mitochondrial and plastid porin (MPP) family 1.B.9 FadL outer membrane protein (FadL) family 1.B.10 Nucleoside-specific channel-forming outer membrane porin (Tsx) family 1.B.11 Outer membrane fimbrial usher porin (FUP) family 1.B.12 Autotransporter-1 (AT-1) family 1.B.13 Alginate export porin (AEP) family 1.B.14 Outer membrane receptor (OMR) family 1.B.15 Raffinose porin (RafY) family 1.B.16 Short chain amide and urea porin (SAP) family 1.B.17 Outer membrane factor (OMF) family 1.B.18 Outer membrane auxiliary (OMA) protein family 1.B.19 Glucose-selective OprB porin (OprB) family 1.B.20 Two-partner secretion (TPS) family 1.B.21 OmpG porin (OmpG) family 1.B.22 Outer bacterial membrane secretin (secretin) family 1.B.23 Cyanobacterial porin (CBP) family 1.B.24 Mycobacterial porin 1.B.25 Outer membrane porin (Opr) family 1.B.26 Cyclodextrin porin (CDP) family 1.B.31 Campylobacter jejuni major outer membrane porin (MomP) family 1.B.32 Fusobacterial outer membrane porin (FomP) family 1.B.33 Outer membrane protein insertion porin (Bam complex) (OmpIP) family 1.B.34 Corynebacterial porins 1.B.35 Oligogalacturonate-specific porin (KdgM) family 1.B.39 Bacterial porin, OmpW (OmpW) family 1.B.42 Outer membrane lipopolysaccharide export porin (LPS-EP) family 1.B.43 Coxiella porin P1 (CPP1) family 1.B.44 Probable protein translocating porphyromonas gingivalis porin (PorT) family 1.B.49 Anaplasma P44 (A-P44) porin family 1.B.48 Curli-like transporters 1.B.54 Intimin/Invasin (Int/Inv) or Autotransporter-3 family 1.B.55 Poly-acetyl-D-glucosamine porin (PgaA) family 1.B.57 Legionella major-outer membrane protein (LM-OMP) family 1.B.60 Omp50 porin (Omp50 Porin) family 1.B.61 Delta-proteobacterial porin (Delta-porin) family 1.B.62 Putative bacterial porin (PBP) family 1.B.66 Putative beta-barrel porin-2 (BBP2) family 1.B.67 Putative beta barrel porin-4 (BBP4) family 1.B.68 Putative beta barrel porin-5 (BBP5) superfamily 1.B.70 Outer membrane channel (OMC) family 1.B.71 Proteobacterial/verrucomicrobial porin (PVP) family 1.B.72 Protochlamydial outer membrane porin (PomS/T) family 1.B.73 Capsule biogenesis/assembly (CBA) family 1.B.78 DUF3374 electron transport-associated porin (ETPorin) family
Sources: en.wikipedia.org
=== Chemotherapy === Chemotherapy is injected directly into the cerebrospinal fluid, either by lumbar puncture ("spinal tap") or through a surgically implanted device called an Ommaya reservoir. Intrathecal Therapy is preferred since intravenous chemotherapy do not penetrate the BBB. The most common chemicals used are liposomal cytarabine (DepoCyte) and intrathecal methotrexate (MTX). The downside of a spinal tap diagnosis is that while it is highly accurate and reliable, it can also report false-negative results. Chemotherapy is delivered intrathecally as it is hard for drugs to make it into the central nervous system. Intrathecal chemotherapy can only penetrate a few millimeters. If the tumor is any thicker, radiation is given to shrink it down. The treatment is done to reduce pressure on the brain caused by any cerebrospinal fluid buildup and to reduce the number of cancer cells causing the pressure. For the best care, patients should see a physician who regularly treats leptomeningeal cancer and is most up-to-date on medicines that penetrate the blood-brain barrier, how to treat the symptoms, and clinical trials that might include patients with leptomeningeal cancer.
=== Classification === Four commonly accepted criteria for classifying patients with MCTD have been published: the Sharp criteria (1987), the Alarcón-Segovia criteria (1987), the Kasukawa criteria (1987), and the Kahn criteria (1991). The Alarcon-Segovia and Kahn criteria have equivalent sensitivity and specificity, and a comparison of the four diagnostic criteria suggests that the Kasukawa criteria provide the best sensitivity, while both Alarcon-Segovia and Kahn criteria have the maximum specificity.
=== Length === Most classical cannabinoids are 21-carbon compounds, but variations in the side-chain length attached to the aromatic ring exist. In THC, CBD, and CBN, the side-chain is a pentyl (5-carbon) chain. Propyl (3-carbon) chain variants are named with the suffix varin (THCV, CBDV, CBNV), while heptyl (7-carbon) chain variants are named phorol (THCP, CBDP).
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.